PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

(2019) Nicole L. Michmerhuizen et al.   MOLECULAR PHARMACOLOGY

CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An In Vitro Study

(2019) TZONG-SHYUAN TAI et al.   ANTICANCER RESEARCH

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

(2017) Jennifer Wheler et al.   ONCOLOGIST

Preclinical models in HNSCC: A comprehensive review

(2017) Benoite Méry et al.   ORAL ONCOLOGY

Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo

(2017) Chih-Chia Yu et al.   Oncotarget

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

(2016) Jessica L. Geiger et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest

(2016) Chih-Chia Yu et al.   PLoS One

Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma

(2015) Dominik Horn et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma

(2015) Wei-Lin Liu et al.   Oncotarget

Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)

(2014) S Skvortsov et al.   BRITISH JOURNAL OF CANCER

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

(2014) L Chang et al.   Cell Death & Disease

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

(2013) Susan Heavey et al.   CANCER TREATMENT REVIEWS

Targeting the PI3K-AKT-mTOR signaling network in cancer

(2013) Khurum H. Khan et al.   Chinese Journal of Cancer

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

(2010) Christian Freudlsperger et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma

(2007) Amir Lavaf et al.   CANCER